PBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Prestige Consumer Healthcare Inc (PBH) does not present a strong buy opportunity for a beginner, long-term investor at this time. The company's recent financial performance shows declining revenue, net income, and EPS, while analysts have lowered price targets and ratings. Additionally, there are no significant positive catalysts or trading signals to justify immediate action. Holding off for now is recommended.
The MACD histogram is positive at 0.275 and expanding, indicating bullish momentum. RSI is at 73.958, suggesting the stock is nearing overbought territory. Moving averages are converging, showing no clear trend. Key resistance levels are at 70.432 and 71.784, while support levels are at 66.054 and 64.702.
Hedge funds are significantly increasing their positions, with a 622.44% rise in buying activity over the last quarter.
Insider selling has increased by 291.04% in the last month. Financial performance in Q3 2026 shows declines in revenue (-2.37%), net income (-23.49%), and EPS (-20.49%). Analysts have lowered price targets and ratings, indicating limited upside potential.
In Q3 2026, revenue dropped to $283.4M (-2.37% YoY), net income fell to $46.7M (-23.49% YoY), and EPS decreased to $0.97 (-20.49% YoY). Gross margin slightly declined to 53.7% (-0.13% YoY).
Recent analyst activity includes Canaccord lowering the price target to $86 from $88 while maintaining a Buy rating, and Jefferies reducing the price target to $66 from $70 with a Hold rating. Analysts highlight challenges in eye care recovery and range-bound stock performance without a significant catalyst like M&A.
